Australia, March 24 -- Halozyme Inc., owns the trademark (2613141) for 'HALOZYME' till Aug. 18, 2035.

Status: protected: Registered/protected

Classes: 5 [Drug delivery agents in the form of liquid for subcutaneous delivery that facilitate the delivery of pharmaceutical preparations; enzymes for medical purposes, namely, for facilitating delivery of fluids or pharmaceuticals; drug delivery agents consisting of pharmaceuticals containing enzymes that facilitate delivery of fluids and a wide range of pharmaceuticals; pharmaceutical preparations for use in the treatment and prevention of metabolic conditions and disorders, endocrine conditions and disorders, diabetes, diabetic complications, hormonal diseases and disorders, dermatological conditions and disorders, and for the treatment of cancer and in hydration; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in aesthetic skin treatments; hyaluronic acid for pharmaceutical purposes, namely, recombinant human hyaluronidase formulation for use in in-vitro fertilization procedures; enzymes for medical purposes, namely, recombinant human hyaluronidase formulation for use in in-vitro fertilization procedures.], 35 [Administration of a discount program enabling patients to obtain discounts on prescription drugs through use of a discount card provided by a copay discount program; business administration of a program enabling patients to obtain discounts on prescription drugs through a cash-pay program for uninsured and underinsured patients.], 36 [Insurance benefits verification and prior authorization assistance in the health industry; copay assistance programs, namely, providing financial assistance to uninsured and underinsured patients for prescription medications.], 42 [Scientific research and development services for the integration of technologies, therapies, and other systems for pharmaceuticals and drug delivery systems.] and 44 [Providing medical information in the field of subcutaneous fluid administration; providing medical information in the field of subcutaneous delivery of a wide range of pharmaceuticals.]

Type of Mark: Word

Date of Acceptance: Jan. 16

Registration Advertised: March 23

For further details contact Gene K. Park Morgan, Lewis & Bockius LLP .

The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2613141.

Disclaimer: Curated by HT Syndication.